The global genetic testing market size was valued at USD 14.49 billion in 2025 and is projected to grow from USD 17.47 billion in 2026 to USD 77.91 billion by 2034, registering a CAGR of 20.55% during the forecast period from 2026 to 2034. North America dominated the genetic testing market with a market share of 42.5% in 2025.
Genetic Testing refers to diagnostic techniques used to analyze DNA, RNA, chromosomes, or proteins to identify inherited disorders, genetic mutations, disease susceptibility, and treatment response. It is widely used in prenatal screening, oncology, rare disease diagnosis, pharmacogenomics, and personalized medicine. Growth is driven by advancements in sequencing technologies, increasing adoption of precision medicine, expanding newborn screening programs, and rising awareness of early disease detection and preventive healthcare.
Download a Free Sample To learn more about this report,
Expansion of Next-Generation Sequencing-Based Genetic Testing
The genetic testing market is increasingly moving toward next-generation sequencing technologies capable of analyzing multiple genes and genetic variants within a single test. Broader sequencing panels can support evaluation of hereditary conditions, cancers, and other complex disorders without requiring separate tests for each genetic target. This is increasing the scope of genetic information available from a single clinical sample and supporting wider adoption of high-throughput genomic testing.
In May 2026, the U.S. Food and Drug Administration approved a liquid-biopsy next-generation sequencing test capable of detecting genetic alterations across hundreds of genes from circulating cell-free DNA.
Growing Use of Genetic Testing for Treatment Selection
Genetic testing is increasingly being incorporated into treatment pathways to identify biomarkers that can determine whether patients may benefit from specific therapies. Companion diagnostic testing is particularly expanding in oncology, where genetic alterations can be used to guide targeted treatment decisions. This is shifting genetic testing from primarily diagnostic or risk-assessment applications toward treatment-selection and precision-medicine applications.
In March 2026, the U.S. Food and Drug Administration approved an updated companion-diagnostic indication for a genetic test to identify ovarian cancer patients with BRCA1 and BRCA2 mutations or genomic instability who may be eligible for a targeted therapy.
Rising Prevalence of Genetic and Hereditary Disorders Supports Testing Demand
The identification and management of inherited disorders require genetic information that cannot always be obtained through conventional clinical assessment. Greater recognition of rare diseases and hereditary conditions is encouraging healthcare systems to use genetic testing to support diagnosis, carrier identification, and family risk assessment. Increasing clinical awareness of genetic contributions to disease is therefore expanding the population referred for testing.
In September 2024, the National Institutes of Health reported that more than 10,000 rare diseases were estimated to affect millions of people in the United States, highlighting the large population potentially requiring genomic approaches for diagnosis and disease characterization.
Complex Interpretation of Genetic Results Limits Wider Utilization
Genetic tests can identify variants whose clinical significance is uncertain or may change as scientific knowledge develops. Interpreting results often requires clinical context, family history, databases of genetic evidence, and specialist expertise. This complexity can make testing more difficult to integrate into routine care and can increase the need for genetic counseling and specialist review.
In February 2025, the U.S. National Human Genome Research Institute continued to identify interpretation of variants of uncertain significance as an important challenge in clinical genomic medicine, particularly when genetic findings do not have established disease associations.
Expansion of Pharmacogenomic Testing Creates New Clinical Applications
Pharmacogenomic testing can identify genetic variations that influence how individuals metabolize or respond to certain medicines. Greater incorporation of genetic information into prescribing decisions could create additional applications for testing across psychiatry, cardiology, oncology, and other therapeutic areas. Integration with clinical decision-support systems can further improve the practical use of pharmacogenomic results.
In April 2025, the Clinical Pharmacogenetics Implementation Consortium continued expanding evidence-based prescribing guidance for gene–drug pairs, supporting broader clinical implementation of pharmacogenomic information.
Unequal Access to Genetic Testing Infrastructure
Access to genetic testing depends on the availability of specialized laboratories, sequencing technologies, trained professionals, genetic counseling, and reimbursement. These resources are unevenly distributed across healthcare systems and geographic regions, creating differences in patients' ability to obtain testing and appropriate interpretation. Infrastructure gaps can therefore limit the broader clinical adoption of advanced genetic testing.
In October 2024, the World Health Organization highlighted persistent inequalities in access to genomic technologies and emphasized the need to strengthen genomic infrastructure and capacity in lower-resource healthcare systems.
Polymerase Chain Reaction (PCR) Dominated the Market with 34.6% Share in 2025
The Polymerase Chain Reaction (PCR) segment accounted for the largest share of the global genetic testing market at 34.6% in 2025, driven by its high accuracy, rapid turnaround time, and widespread use in detecting inherited disorders, infectious diseases, and genetic mutations. Its cost-effectiveness, ease of implementation in clinical laboratories, and broad adoption across diagnostic and research applications continue to reinforce the segment’s market leadership.
Request Customizationto receive a tailored report.
Genetic Disease Carrier Status is Projected to Register the Fastest Growth at a CAGR of 12.6%
The Genetic Disease Carrier Status segment is expected to expand at the fastest CAGR of 12.6% during 2026–2034, supported by increasing awareness of inherited disorders, growing adoption of preconception and prenatal screening, and expanding access to personalized healthcare services. Rising demand for early risk assessment, genetic counseling, and preventive healthcare is further accelerating growth in this application segment.
Consumables Dominated the Market with 52.8% Share in 2025
The Consumables segment held the largest market share of 52.8% in 2025, owing to the recurring demand for reagents, assay kits, sample preparation materials, and laboratory supplies used in genetic testing procedures. The increasing volume of diagnostic testing, continuous advancements in molecular diagnostics, and growing adoption of next-generation sequencing technologies continue to strengthen the segment’s dominant position.
Diagnostic Laboratories are Projected to Register the Fastest Growth at a CAGR of 12.1%
The Diagnostic Laboratories segment is expected to grow at the fastest CAGR of 12.1% during 2026–2034, driven by increasing demand for high-throughput genetic testing, expanding laboratory infrastructure, and rising investments in precision medicine. The growing availability of advanced molecular diagnostic platforms, automation technologies, and specialized genetic testing services is further accelerating the adoption of genetic testing in diagnostic laboratories.
Speak to an Analystto discuss market opportunities.
North America dominated the genetic testing market with a 42.5% market share, valued at USD 6.16 billion in 2025. The region is projected to grow at a CAGR of 10.8% during the forecast period. Growth is driven by advanced healthcare infrastructure, widespread adoption of precision medicine, increasing prevalence of hereditary disorders, and strong investments in genomic research. The presence of leading biotechnology companies and favorable reimbursement policies further supports regional market expansion.
The United States accounted for an estimated USD 5.43 billion of the market in 2025, making it the largest contributor in North America. Growth is supported by increasing adoption of next-generation sequencing (NGS), expanding precision medicine initiatives, rising demand for hereditary cancer screening, and significant investments in genomic research and diagnostics.
Canada generated an estimated USD 0.73 billion in 2025. Rising investments in genomic medicine, expanding public healthcare initiatives, growing awareness of genetic disorders, and increasing adoption of personalized healthcare continue to support market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe accounted for 27.3% of the genetic testing market, reaching USD 3.96 billion in 2025. The market is supported by expanding genomic research programs, increasing implementation of precision medicine, growing demand for prenatal and oncology testing, and strong government support for genetic diagnostics. Continuous investments in biotechnology and healthcare innovation contribute to regional expansion.
Germany led the European market with an estimated value of USD 0.98 billion in 2025. The country's advanced healthcare system, robust biotechnology sector, increasing adoption of molecular diagnostics, and strong focus on precision medicine continue to drive market growth.
The United Kingdom represented an estimated USD 0.63 billion in 2025. Growth is driven by national genome sequencing initiatives, increasing use of genetic screening in clinical practice, expanding cancer diagnostics, and rising investments in personalized medicine.
Asia Pacific accounted for 20.6% of the genetic testing market, valued at USD 2.98 billion in 2025. The region is projected to grow at the fastest CAGR of 13.9% during the forecast period. Growth is fueled by increasing healthcare expenditure, expanding genomic research, rising awareness of inherited diseases, and growing adoption of advanced molecular diagnostic technologies. Government initiatives supporting precision medicine continue to strengthen regional market growth.
China accounted for an estimated USD 1.37 billion in 2025, making it the largest market in Asia Pacific. Growth is supported by expanding genomic sequencing capabilities, increasing investments in biotechnology, rising demand for prenatal and oncology testing, and strong government support for precision medicine.
Japan generated an estimated USD 0.72 billion in 2025. The country's advanced healthcare infrastructure, growing adoption of genomic diagnostics, increasing focus on personalized medicine, and expanding research in rare genetic disorders continue to support steady market growth.
Latin America accounted for 5.4% of the genetic testing market, reaching USD 0.78 billion in 2025. Increasing awareness of hereditary diseases, expanding access to molecular diagnostics, improving healthcare infrastructure, and growing investments in precision medicine are supporting regional market growth.
Brazil accounted for an estimated USD 0.34 billion in 2025, making it the largest market in Latin America. Growth is supported by increasing demand for prenatal and cancer genetic testing, expanding diagnostic laboratories, and improving access to advanced genomic technologies.
The Middle East & Africa represented 4.2% of the genetic testing market, totaling USD 0.61 billion in 2025. Increasing investments in healthcare infrastructure, rising awareness of inherited disorders, expanding molecular diagnostic services, and growing adoption of precision medicine are supporting regional market expansion.
The United Arab Emirates (UAE) accounted for an estimated USD 0.16 billion in 2025. The country's market is driven by healthcare digital transformation, expanding genomic medicine initiatives, increasing adoption of advanced diagnostic technologies, and rising investments in personalized healthcare and preventive screening programs.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Amniotic Membrane Market Size, Share, Growth, Forecast, 2034
Cancer Stem Cell Market Size, Share, Growth, Forecast, 2034
Cell Surface Markers Detection Market Size, Share, Growth, 2034
Blood Testing Market Size, Share, Growth, Analysis, Report, 2034
Cancer Biologics Market Size, Share, Growth, Forecast, 2034
Petri Dishes Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com